News

A Phase 3 clinical trial aiming to assess the safety and efficacy of nipocalimab in pregnancies at risk of FNAIT is set to begin soon.

A recent case report describes a case of suspected FNAIT in Nigeria that ultimately resulted in the death of the infant.

In a recent study, Rallybio’s new therapy, RLYB212, successfully prevented fetal and neonatal alloimmune thrombocytopenia in mice.

A recent survey of mothers affected by FNAIT highlighted the risks of a second pregnancy after a previous pregnancy resulted in ICH.

A recent survey shows that children affected by FNAIT may be at greater risk of being diagnosed with autism later in life.

The distinct patterns of perinatal intracranial hemorrhage (pIH), a feared FNAIT complication, were detailed in a recent study.

Like FNAIT, maternal immune thrombocytopenic purpura (ITP) can lead to thrombocytopenia in newborns, according to a recent study.

A recent report detailed the first case of FNAIT logged at a 180-year-old institution in India, complete with treatment methods and outcomes.

A Phase 2 clinical trial for an experimental treatment for FNAIT was recently approved by the European Medicines Agency.

A recent analysis described how the use of artificial intelligence (AI) is being integrated into infant health care and disease prediction.